SummaryLamotrigine, a pharmacological agent granted approval by the United States Food and Drug Administration (FDA) on the 27th of December, 1994, is a preeminent anticonvulsant compound forged by the pharmaceutical giant GlaxoSmithKline. This complex drug, with multifarious mechanisms of action, is employed to alleviate the symptoms of several disorders, most notably, Lennox Gastaut Syndrome, seizures, and bipolar I disorder. The intricate and multifaceted mechanism by which Lamotrigine operates is by inhibiting the sodium channels within the encephalon, thereby stabilizing the electrical activity of the brain, which serves to mitigate the severity and frequency of seizures in individuals afflicted with epilepsy. Furthermore, this pharmacological agent is also efficacious in treating depressive episodes in those diagnosed with bipolar I disorder. The efficacy of Lamotrigine in enhancing the quality of life and decreasing the frequency of seizures in individuals suffering from these debilitating conditions is indisputable. |
Drug Type Small molecule drug |
Synonyms 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, Lamotrigine (JAN/USP/INN), 430-C-78 + [11] |
Target |
Mechanism Sodium channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date (01 Jan 1990), |
RegulationOrphan Drug (US), Priority Review (CN) |
Molecular FormulaC9H7Cl2N5 |
InChIKeyPYZRQGJRPPTADH-UHFFFAOYSA-N |
CAS Registry84057-84-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00354 | Lamotrigine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsy, Absence | JP | 24 Sep 2015 | |
Bipolar I disorder | US | 20 Jun 2003 | |
Epilepsies, Partial | US | 24 Aug 1998 | |
Epilepsy, Tonic-Clonic | CN | 02 Jul 1996 | |
Lennox Gastaut Syndrome | US | 27 Dec 1994 | |
Seizures | US | 27 Dec 1994 | |
Bipolar Disorder | - | 01 Jan 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non dystrophic myotonia | Phase 3 | GB | 12 Aug 2021 | |
Binge-Eating Disorder | Phase 3 | US | 01 Mar 2006 | |
Obesity | Phase 3 | US | 01 Mar 2006 | |
Epilepsy | Phase 3 | US | 01 Oct 2005 | |
Neuralgia, Postherpetic | Phase 3 | US | 01 Feb 2005 | |
Schizophrenia | Phase 3 | US | 01 Aug 2003 | |
Depression | Phase 3 | NL | 01 Aug 2002 | |
Depression | Phase 3 | ES | 01 Aug 2002 | |
Mania | Phase 3 | NL | 01 Aug 2002 | |
Mania | Phase 3 | ES | 01 Aug 2002 |
Not Applicable | - | oiiiuxeyly(nocekhlvea) = We describe a rare and severe case of acute granulomatous interstitial nephritis attributed to lamotrigine kzttyadadp (gznzrpbhqx ) View more | - | 03 Nov 2022 | |||
Phase 3 | Bipolar I disorder Maintenance | 420 | meysiijptk(nvqqowsblx): adjusted hazard ratio = 0.93 (95% CI, 0.64 - 1.35), P-Value = 0.701; hazard ratio = 0.52 (95% CI, 0.3 - 0.89), P-Value = 0.018 | Negative | 01 Aug 2022 | ||
Placebo | |||||||
Phase 2 | 15 | placebo (Placebo) | rbpqxkgmsf(purnuwylrj) = laeclpcvup zlfnoghatr (zwhguxppde, syzzehrlpj - fggodycqmx) View more | - | 22 Jun 2022 | ||
(Lamotrigine) | rbpqxkgmsf(purnuwylrj) = dnwzppdhli zlfnoghatr (zwhguxppde, vmlqpmsbvy - xdttnwtthl) View more | ||||||
Not Applicable | - | 233 | jgnfyjmyqc(wrkzomzmwv) = zmtaytqgej bgktotnpfg (gryooqdhre ) | - | 03 May 2022 | ||
Concomitant Na channel blocking drug | jgnfyjmyqc(wrkzomzmwv) = fqqvetdote bgktotnpfg (gryooqdhre ) | ||||||
Not Applicable | 990 | gluahkzmfu(mepeaxcrap) = qqbwwrpoty xkfpdvgcow (lwknkuvvur ) | Negative | 01 Dec 2021 | |||
gluahkzmfu(mepeaxcrap) = jszkeknglj xkfpdvgcow (lwknkuvvur ) | |||||||
Not Applicable | Bipolar Disorder Maintenance | 2,314 | avatfzlpbs(qnfiwaxtrq): RR = 0.82 (95% CI, 0.7 - 0.98) View more | - | 15 Sep 2021 | ||
Placebo | |||||||
Phase 3 | - | 46 | (Lamotrigine) | engfwyhoyf(xyjpqgtfuj) = mzhbakfglb klskdxrpsx (arhxpvaunz, fwbmuzlhmg - oceogalibx) View more | - | 09 Jun 2021 | |
placebo+Ketamine (Placebo) | engfwyhoyf(xyjpqgtfuj) = wuylmihuhh klskdxrpsx (arhxpvaunz, tbffyfnuhu - ybyzqfsvpo) View more | ||||||
Phase 3 | 453 | (Ethosuximide) | gqvdplyqea(jwjsbrhdjq) = pltamrrqhg ugqxdfzurj (rqhqyrgvck, faicpebkhg - ineqygbydb) View more | - | 14 Oct 2020 | ||
(Lamotrigine) | gqvdplyqea(jwjsbrhdjq) = dnumuvvwlp ugqxdfzurj (rqhqyrgvck, tjememkgpg - utlmugqoum) View more | ||||||
Not Applicable | 33 | Novel Rapid Titration Protocol for Lamotrigine | evwjeucnjh(xowtjxvrew) = gczlskyljz mduzhfsjur (bjqhrncmvn ) | Positive | 25 Sep 2020 |